Prognosis of recurrent non-small cell lung cancer following complete resection.
Prognosis of recurrent non-small cell lung cancer following complete resection.
复制标题
DOI：
10.3892/ol.2014.1861
复制
发表时间：
2014-04
期刊：
影响因子：
2.9
通讯作者：
Fujii Y
中科院分区：
文献类型：
--
作者：
Sasaki H;Suzuki A;Tatematsu T;Shitara M;Hikosaka Y;Okuda K;Moriyama S;Yano M;Fujii Y
非小细胞肺癌（NSCLC）完全切除后复发的预后被认为是一个多因素过程，取决于临床病理学、生物学和治疗特征。吉非替尼于 2002 年在日本被批准用于肺癌治疗。当前研究的目的是量化这些特征对复发后预后的影响。总共对 127 名接受完全切除但随后癌症复发的 NSCLC 患者进行了分析。研究了初始和复发疾病的特征与复发后预后之间的相关性。使用Cox比例风险模型，与复发后预后明显相关的因素是复发时的年龄（年龄<65岁的患者通常有更好的预后）以及初次切除和复发之间的间隔（间隔<1年伴随着更差的预后）。在样本中，接受 EGFR 酪氨酸激酶抑制剂 (TKI) 治疗的表皮生长因子受体 (EGFR) 突变患者在复发后表现出最长的中位生存期（37.4 个月）。据观察，治疗，尤其是针对复发性 NSCLC 的 EGFR TKI 治疗，可显着延长生存期。研究结果强调，对于术后复发的 NSCLC 患者，应根据患者的临床背景考虑采用各种治疗方式。
Prognosis following recurrence subsequent to complete resection of non-small-cell lung cancer (NSCLC) is considered a multifactorial process dependent on clinicopathological, biological and treatment characteristics. Gefitinib was approved for lung cancer treatment in Japan in 2002. The aim of the current study was to quantify the prognostic effects of these characteristics on post-recurrence prognosis. In total, 127 NSCLC patients were analyzed who underwent complete resection and subsequently had recurrent cancer. The correlation between characteristics of the initial and recurrent disease with post-recurrence prognosis was investigated. The factors clearly associated with post-recurrence prognosis using Cox proportional hazards models were age at recurrence (those <65 years of age typically had better prognoses) and interval between initial resection and recurrence (intervals of <1 year accompanied a worse prognosis). Epidermal growth factor receptor (EGFR) mutant patients treated with EGFR tyrosine kinase inhibitors (TKIs), exhibited the longest median survival following recurrence (37.4 months) in the sample. Treatment, particularly EGFR TKIs for recurrent NSCLC, was observed to significantly prolong survival. The results of the study highlight that various treatment modalities according to the clinical background of the patient should be considered in patients with postoperative recurrent NSCLC.
登录
查看更多内容
DOI：
10.1093/annonc/mdq020
发表时间：
2010-09
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子：
--
作者：
Reck M;von Pawel J;Zatloukal P;Ramlau R;Gorbounova V;Hirsh V;Leighl N;Mezger J;Archer V;Moore N;Manegold C;BO17704 Study Group
通讯作者：
BO17704 Study Group
影响因子：
158.5
作者：
Lynch, TJ;Bell, DW;Haber, DA
通讯作者：
Haber, DA
影响因子：
51.1
作者：
Mitsudomi, Tetsuya;Morita, Satoshi;Fukuoka, Masahiro
通讯作者：
Fukuoka, Masahiro
影响因子：
45.3
作者：
Scagliotti, Giorgio Vittorio;Parikh, Purvish;Gandara, David
通讯作者：
Gandara, David
影响因子：
11.5
作者：
Sasaki, H;Endo, K;Fujii, Y
通讯作者：
Fujii, Y